Brought to you by 
Eisai licenses rights to Zonegran from Elan
Apr 2004
Executive Summary
Elan Corp. PLC, the original licensee of North American and European rights to Dainippon Pharmaceutical's Zonegran, has transferred these rights to Eisai. Zonegran (zonisamide) is an FDA-approved drug to treat partial seizures in adult epileptic patients.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eisai licenses rights to Zonegran from Elan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice